Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have received an average rating of “Buy” from the thirteen ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $107.00.

A number of equities analysts have recently issued reports on the company. BTIG Research reissued a “buy” rating and set a $104.00 price target on shares of Monopar Therapeutics in a research report on Monday, February 23rd. Wall Street Zen lowered shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Leerink Partners started coverage on shares of Monopar Therapeutics in a research report on Monday, November 10th. They set an “outperform” rating and a $115.00 target price on the stock. Chardan Capital restated a “buy” rating and issued a $100.00 price target on shares of Monopar Therapeutics in a report on Thursday, January 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, January 22nd.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $54.81 on Friday. Monopar Therapeutics has a 1-year low of $26.06 and a 1-year high of $105.00. The firm has a market capitalization of $366.13 million, a P/E ratio of -15.93 and a beta of 1.52. The company’s 50-day moving average is $63.58 and its 200 day moving average is $67.55.

Insiders Place Their Bets

In other news, CFO Quan Anh Vu acquired 1,500 shares of the business’s stock in a transaction dated Friday, December 26th. The shares were acquired at an average cost of $69.95 per share, with a total value of $104,925.00. Following the completion of the acquisition, the chief financial officer owned 1,500 shares of the company’s stock, valued at approximately $104,925. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

A number of large investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in Monopar Therapeutics in the 4th quarter valued at $654,000. Invesco Ltd. purchased a new position in Monopar Therapeutics during the fourth quarter valued at $219,000. ADAR1 Capital Management LLC lifted its holdings in Monopar Therapeutics by 79.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 233,908 shares of the company’s stock valued at $15,274,000 after purchasing an additional 103,909 shares in the last quarter. Virtus Investment Advisers LLC acquired a new stake in shares of Monopar Therapeutics in the fourth quarter valued at about $233,000. Finally, Millennium Management LLC increased its stake in shares of Monopar Therapeutics by 945.5% during the fourth quarter. Millennium Management LLC now owns 76,674 shares of the company’s stock worth $5,007,000 after purchasing an additional 69,340 shares in the last quarter. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.